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Context: Vitamin D has several effects on the immune system that might be of relevance for the
pathogenesis of type 1 diabetes (T1D).
Objective: To evaluate whether umbilical cord serum concentrations of 25-hydroxy-vitamin D (25[OH]D)
differ in childrendevelopingeither islet autoimmunity (IA)orovert T1Dduring childhoodandadolescence.
Design: Umbilical cord serum samples from 764 children born from 1994 to 2004 with HLA-DQB1
conferred risk for T1D participating in the Type 1 Diabetes Prediction and Prevention Study were
analyzed for 25(OH)D using an enzyme immunoassay.
Setting: DIPP clinics in Turku, Oulu, and Tampere University Hospitals, Finland.
Participants: Two hundred fifty children who developed T1D diabetes at a median age of 6.7 years
(interquartile range [IQR] 4.0 to 10.1 years) and 132 additional case children who developed IA, i.e.,
positivity for multiple islet autoantibodies. Cases were matched for date of birth, gender, and area
of birth with 382 control children who remained autoantibody negative. The median duration of
follow up was 9.8 years (IQR 5.7 to 13.1 years).
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Main Outcome Measure: The median 25(OH)D concentrations.
Results: The median 25(OH)D concentration in cord serum was low [31.1 nmol/L (IQR 24.0 to 41.8);
88% ,50 nmol/L], but not statistically different between children who developed T1D or IA and
their control groups (P = 0.70). The levels were associated mainly with geographical location, year
and month of birth, age of the mother, and maternal intake of vitamin D during pregnancy.
Conclusions: The 25(OH)D concentrations at birth are not associated with the development of T1D
during childhood. (J Clin Endocrinol Metab 104: 2277–2285, 2019)
V itamin D is one of the essential players in metabolicand physiological processes in the human body.
It has multiple effects on the immune system and its
role in the pathogenesis of immune-mediated diseases
has long been suspected. We noticed an increase in 25-
hydroxyvitamin D (25[OH]D) concentrations in Finnish
children after year 2003, when vitamin D fortification of
milk started in Finland, which preceded the plateauing of
the rapid increase in type 1 diabetes (T1D) incidence that
had continued for more than 50 years (1). However, we
found no difference in median 25(OH)D concentration
between children who developed T1D and healthy
matched control children when the children were ob-
served from the age of three months until the diagnosis of
T1D (2).
T1D is an immune-mediated disease, which can
manifest at any age (3). Diagnosis in early childhood,
before the age of four years, is quite common espe-
cially in Finland, where the incidence is highest in the
world (4) and some children develop T1D even before
the age of one year (5). The factors initiating or
triggering the immune-mediated process leading to the
disease must be operative before that, perhaps already
during fetal life. Some changes can be seen early on
and we have detected differences in the lipidomic
profile in cord serum samples in children who later
progressed rapidly to T1D, but not in those developing
islet autoimmunity (IA) without progressing to overt
disease (6).
Here we assessed the possible association of fetal vi-
tamin D levels and the development of IA and progres-
sion to clinical T1D by measuring umbilical cord serum
25(OH)D concentration in the Type 1 Diabetes Pre-
diction and Prevention Study (DIPP) birth cohort study.
Furthermore, we analyzed maternal intake of vitamin D
during pregnancy in a subcohort.
Materials and Methods
The study population comprised children (born between 1994
and 2004), who participated in DIPP in Finland. The DIPP
project is an ongoing population-based prospective birth
cohort study aimed at exploring means to predict and prevent
progression to clinical type 1 diabetes (T1D) (7). Briefly,
newborn infants with HLA-DQB1–conferred susceptibility to
T1D are recruited from the University Hospitals in Turku
(located at 60 °N), Oulu (located at 65 °N), and Tampere
(located at 61 °N), Finland. The children attend the study
centers for follow-up visits at 3- to 12-month intervals and
their serum samples are analyzed for T1D-related autoanti-
bodies. Islet cell antibodies (ICA) were used as the primary
screening tool for b-cell autoimmunity. If a child sero-
converted to positivity for ICA, all the preceding and sub-
sequent samples of this child were analyzed for insulin
autoantibodies (IAA), antibodies to the 65 kDa isoform of
glutamic acid decarboxylase (GADA), and to the tyrosine
phosphatase-related islet antigen 2 (IA-2A). Data from the
autoantibody-negative children participating in the follow-up
were collected until they were 15 years of age or until the end
point of this study (July 2016). Data from the autoantibody-
positive children were collected until the follow-up for this
study ended or until they were diagnosed with T1D according
to the World Health Organization criteria, whichever came
first.
We analyzed the concentration of 25-hydroxyvitamin D (25
[OH]D) in umbilical cord serum samples from 764 DIPP study
participants with a nested case control design. There were 133
case control pairs in the Turku cohort, 137 in the Oulu cohort,
and 112 in the Tampere cohort. Case children comprised two
groups; the majority of the cases (250 children) were diagnosed
with T1D by the end of July 2016 (T1D+) and the minority of
cases (132 children) showed IA testing positive for multiple
($2) autoantibodies but not progressing to overt T1D by the
end of the study period (IA+). The cases were included based on
the availability of samples and one control subject was selected
for each case child. All control subjects (T1D2 and IA2)
remained autoantibody-negative and nondiabetic throughout
the follow-up, and they were pairwise matched for age (birth
within 30 days), gender, and study center.
Mixed arterial/venous umbilical cord blood was collected in
the delivery room and these samples were used for both serum
extraction and genetic screening. Serum samples were stored
at 270°C. All children were initially screened for HLA-DQB1
alleles (8). An extended six-scale HLA-DR/DQ genotype-based
T1D risk classification (9) was available in 625 of the 764
children. The three groups with decreased or neutral risk were
combined into a nonincreased risk group, as the number of
children in these groups was small. One child (IA+) carried a
genotype conferring strongly decreased risk, 6 children (2 IA2
and 4 T1D2) had genotypes conferring slightly decreased risk,
and 28 children (7 IA+, 10 IA2, 2 T1D+, and 9 T1D2) carried
genotypes conferring neutral risk, so that the nonincreased risk
group included 35 children, whereas there were 135 children
(30 IA+, 28 IA2, 33 T1D+, and 44 T1D2) with slightly in-
creased risk, 279 children (71 IA+, 29 IA2, 125 T1D+, and 54
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T1D-) with moderately increased risk, and 176 children (23
IA+, 16 IA2, 89 T1D+, and 48 T1D2) with genotypes conferring
highly increased risk for T1D.
We were able to obtain maternal dietary data collected by a
validated food frequency questionnaire after the birth of the
child. The mothers were asked for food consumption during
one month preceding the pregnancy leave, i.e., the eighth month
of pregnancy. Total energy intake and vitamin D intake from
food, supplements, and in total were used in the current study,
as described by Marjama¨ki et al. (10), from the mothers of 363
children in this study (63 IA+, 60 IA2, 121 T1D+, and 119
T1D2); 168 in the Oulu and 195 in the Tampere cohorts.
A commercial immunoassay kit (Immunodiagnostic Systems
Ltd, Boldon, UK) was used for the 25(OH)D analyses, as
previously described (1). The intra-assay coefficient of variation
was 6.5% and the sensitivity was 5 nmol/L. The performance
target set by the Vitamin D External Quality Assessment
Scheme Advisory Panel for 25(OH)D assays was met (11).
Statistical analyses were performed with JMP Pro 12.0.1 and
SAS for Windows version 9.4 (SAS Institute, Cary, NC) using
multiway analysis of variance and Fisher exact test for cate-
gorical variables. Season of birth and study center were used as
adjusting factors in all analysis. The value of P , 0.05 (two-
tailed) was taken to indicate statistical significance. The year
was divided into seasons as in our previous studies (1, 2), i.e.,
winter (January toMarch), spring (April to June), summer (July
to September), and fall (October to December). The 25(OH)D
concentrations, energy intake and vitamin D intake from food,
supplements and in total, were log-transformed responses in
analyses requiring normal distribution. As zero values cannot
be log transformed, 0.1 mg was added to vitamin D intake
values from supplements to enable the log transformation and
analysis. Possible confounding factors were controlled for by
adding background variables to the statistical models as de-
scribed in the Results section.
The current study was conducted according to the guidelines
of the Declaration of Helsinki and was approved by the
Joint Commission on Ethics of Turku University and Turku
University Central Hospital. Written in-
formed consent was obtained from all
guardians of the subjects.
Results
Altogether, the study cohort included
382 case (250 T1D+, 132 IA+) and
382 control (250 T1D2, 132 IA2)
children, who were matched for age,
gender, and study center, as described.
Serum 25(OH)D concentrations were
statistically significantly affected by
month of birth (Fig. 1) (P = 0.002) and
study center (P = 0.03), so that the
children of the Oulu center (the most
northern of the of the centers located
at 65°N) had substantially lower
levels than the children in Turku
(60°N) and Tampere (61°N) centers,
but not by gender(P = 0.64). As dates
of birth of cases and their controls were matched within
one month, the age difference between them was small,
the median being 6.5 days (IQR 2 to 13 days) for T1D+
and T1D2, and 6 days (IQR 3 to 15) for IA+ and IA2
participants. The children were born rather evenly
around the year. There were 210 children born in the
winter (62 T1D+, 63 T1D2, 44 IA+, and 41 IA2); 182
children born in the spring (64 T1D+, 61 T1D-, 28 IA+,
and 29 IA2); 187 born in the summer (59 T1D+, 62
T1D2, 33 IA+, and 33 IA2); and 185 born in the fall
(65 T1D+, 64 T1D2, 27 IA+, and 29 IA2).
The basic characteristics were similar between the
study groups T1D+, T1D2, IA+, and IA2 (Table 1). As
anticipated (12), the T1D+ children seroconverted to
autoantibody positivity at an earlier age than IA+ chil-
dren, and the follow-up time was shorter in the T1D+
group because of the design of the study.
Most importantly, there were no statistically significant
differences in the median 25(OH)D concentrations in cord
serum between the study groups (P = 0.70). The 25(OH)D
concentrations of 675 cord serum samples were below
50 nmol/L and thus 88% of the study children had sub-
optimal (13) vitamin D levels.Whenmonths were combined
to seasons of birth, its significance on 25(OH)D concen-
trations increased (from P = 0.002 to P , 0.0001), with a
peak concentration during the summer months (Fig. 1).
The association between 25(OH)D concentrations
and group differences (T1D+, T1D2, IA+, IA2) was
studied with multiway ANOVA. Also, these analyses
were adjusted by season and study center. All interactions
between the independent explanatory variables were
evaluated and if they were nonsignificant they were
Figure 1. Monthly distribution of median 25(OH)D concentrations in cord serum samples
were similar in the four groups. There were no statistically significant differences between
T1D+ (solid black line) and T1D2 (dashed black line) children (P = 0.39) or between IA+
(dashed gray line) and IA2 (short-dashed gray line) children (P = 0.63). Serum 25(OH)D
concentrations were statistically significantly affected by month of birth (P = 0.002).
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removed from the final model. In addition, the effect of
year of birth, HLA-DQB1 group, HLA-DR/DQ group,
number of antibodies, ponderal index, and nutritional
factors with 25(OH)D concentration were evaluated in
separate models with the analysis method explained
above. Differences between the groupswere nonsignificant
in all the models reported below.
The median age at the diagnosis of T1D was 6.7 years
(IQR 4.0 to 10.9 years). The median age at serocon-
version to autoantibody positivity in the T1D+ group
was 2.0 years (IQR 1.1 to 4.0) (n = 235, information was
not available for 15 subjects) and 4.0 years (IQR 1.8 to
6.2) in the IA+ group (n = 132). The 25(OH)D con-
centrations were not associated with the age at T1D
diagnosis (P = 0.53) nor with the age of seroconversion to
autoantibody positivity (P = 0.72).
During the follow-up there were 146 T1D+ and 31 IA+
children who tested positive for all four autoantibodies,
64 T1D+ and 45 IA+ children positive for three auto-
antibodies, 22 T1D+ and 56 tested maximally positive
for two autoantibodies, and additional 6 T1D+ children
tested positive for the maximum of one autoantibody in
their sample series, and 12 T1D+ children had unknown
autoantibody status (i.e., incomplete set of samples
available for antibody analysis) before the diagnosis of
T1D. There were no statistically significant differences in
25(OH)D concentrations between these autoantibody
groups (P = 0.38). The situation was similar when only
biochemical autoantibodies were considered as were the
numbers of children involved; there were 146 T1D+ and
31 IA+ children with three biochemical autoantibodies,
65 T1D+ and 46 IA+ with two, 24 T1D+ and 55 IA+
children with one, and three T1D+ children with only
ICA, i.e., zero biochemical autoantibodies, all having
similar 25(OH)D concentrations (P = 0.32).
There were 11 IA+ and 86 T1D+ children with IAA as
the first appearing persistent biochemical autoantibody.
No differences were found in 25(OH)D concentrations
(P = 0.61) between the groups of cases and their matched
97 controls in this subcohort. Similar results were ob-
tained in the 70 IA+ and 39 T1D+ children in whom
GADA was the first appearing persistent autoantibody;
no differences were seen between the cases and their 109
controls (P = 0.51).
HLA-DQB1 group (moderate risk, high risk) was not
associated 25(OH)D concentrations (P = 0.57), neither
were the extended HLA-groups (nonincreased risk,
slightly increased risk, moderately increased risk, and
highly increased risk in HLA-DR/DQ) (P = 0.46).
The age of the mother at the time of birth was posi-
tively associated with 25(OH)D concentration (P =
0.002) cord serum with higher concentration in older
mothers. The median age of the mother was 29.8 (IQR
26.6 to 33.6) years, and it was highest in Turku [30.2
(IQR 26.6 to 33.7) years] and lowest in Oulu [29.4 (26.3
to 33.0) years]. The ponderal index of the child, calcu-
lated as weight in kilogram per height cubed, was in-
versely associated with 25(OH)D concentrations (P =
0.031), but there was no statistically significant associ-
ation with either weight (P = 0.29) or length (P = 0.75)
alone to 25(OH)D. The ponderal index did not correlate
with the age of the mother (P = 0.16).
Almost 10% of the mothers had smoked during
pregnancy (70 smoking, 655 nonsmoking, 39 not
known). There were mothers who had smoked in all
groups: 20 were mothers to T1D+ children, 26 to T1D2
children, 9 to IA+ children, and 15 to IA2children.
Maternal smoking (yes/no) during pregnancy was not
associated with 25(OH)D concentration in cord serum
(P = 0.40) and neither was the mode of delivery when all
Table 1. General Characteristics of the Study Population
T1D+ N = 250 T1D2 N = 250 IA+ N = 132 IA2 N = 132 P
25(OH)D, nmol/L 30.7
(22.9– 43.3)
31.1
(24.5–39.8)
30.7
(23.3–41.8)
31.2
(25.2–40.5)
0.70
Weight, kg 3.59
(3.26–3.90)
3.65
(3.30–3.97)
3.64
(3.26–3.97)
3.63
(3.33–3.90)
0.76
Height, cm 50
(49–52)
51
(49–52)
51
(49–52)
50
(49–52)
0.58
Seroconversion age, y 2.0
(1.1–4.0)
NA 4.0
(1.8–6.2)
NA <0.001
Age at T1D diagnosis, y 6.7
(4.0–10.1)
NA NA NA
Gestational age, wk 39.9
(38.7–40.7)
40.1
(39.0–40.9)
39.9
(38.7–40.7)
40
(38.9–41)
0.32
Age of mother, y 30.1
(26.9–33.9)
29.2
(26.4–32.7)
29.8
(26.0–34.8)
29.8
(26.8–33.7)
0.45
Time of follow-up, y 6.2
(3.4–9.3)
10.5
(6.9–14.3)
12.6
(9.1–14.8)
12.0
(8.4–14.7)
<0.001
Values are median (IQR). The value of P , 0.05 (two-tailed) was taken to indicate statistical significance and is marked in bold.
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modes (vaginal delivery, emergency cesarean section,
planned cesarean section, or assisted delivery) were taken
into account (P = 0.17).
Because some have found cord serum 25(OH)D con-
centration quartiles to be an important factor in relation to
T1D odds (14), we decided to analyze those as well.
However, when we divided the samples into quartiles
based on the 25(OH)D concentration (Table 2), the overall
difference between the groups (T1D+, T1D2, IA+, and
IA2) remained statistically nonsignificant (P = 0.29),
whereas study center and season remained statistically
significant (P = 0.003 and P , 0.001, respectively).
Nutrition during pregnancy
Wewere able to obtain nutritional information from the
eighthmonth of pregnancy in almost half (48%)of the study
population, as 61% of the Oulu and 87% of the Tampere
cohorts participated in the DIPP Nutrition Study. The
general characteristics of the subpopulation for which nu-
tritional information was available are presented in Table 3.
Maternal intake of vitamin D during pregnancy
showed a statistically significant association with um-
bilical cord serum 25(OH)D concentrations in all forms,
from food (P, 0.0001), from supplements (P, 0.0001),
and in total (P , 0.0001). The energy intake was not
associated with 25(OH)D concentration (P = 0.27).
The age of the mother had a statistically significant
association with 25(OH)D concentration also in this
subpopulation (P = 0.025), but age did not correlate with
energy intake (P = 0.64), vitamin D intake from food
(P = 0.22), intake from supplements (P = 0.51), nor with
total vitamin D intake (P = 0.22). The median age of
mothers was in the same range [29.3 years (IQR 26.4 to
33.4)] in this subpopulation as it was in the entire study
cohort [29.8 years (IQR 26.6 to 33.6)].
Ponderal index of the infant was not associated with the
25(OH) concentration in this subpopulation (P = 0.097) but
its correlation with the age of the mother was close to
significant (P = 0.059). Ponderal index did not correlate
with energy intake (P = 0.34), vitamin D intake from food
(P = 0.30), from supplements (P = 0.52), nor with total
vitaminD intake (P = 0.93) of themother during pregnancy.
When divided into the same quartiles based on 25(OH)
D quarters as the entire data set (Table 4), there were no
statistically significant differences in the proportion of
children participating, or in energy intake in each quartile,
but there were differences in vitamin D intake from food
(P , 0.001), from supplements (P , 0.001), and in total
(P , 0.001).
The total vitamin D intake during pregnancy was quite
low, as there were only 72 children (20%) in this cohort
whose mothers reported a total vitamin D intake during
pregnancy $10 mg per day; 22 T1D+, 29 T1D2, 14 IA+,
and 7 IA2. Themedian 25(OH)D concentration in these 72
serum samples was 39.1 (IQR 30.1 to 46.6) nmol/L.
The use of vitamin D supplementation during preg-
nancy was uncommon, with only 33 mothers (9%)
getting$5 mg vitamin D from supplements.; 10 T1D+, 13
T1D2, 6 IA+, and 4 IA2. The supplement use was equally
distributed between seasons; nine inwinter, seven in spring,
Table 2. Subjects Divided Into Quarters Based on 25(OH)D Concentration
Q1 (n = 191) Q2 (n = 191) Q3 (n = 191) Q4 (n = 191)
P
20.14
(9.40–24.00)a
27.75
(24.00–31.06)a
34.95
(31.06–41.72)a
49.27
(41.76–135.1)a
T1D+ / T1D2 / IA+ / IA- 74 / 55 / 35 / 27 52 / 69 / 34 / 36 55 / 70 / 30 / 36 69 / 56 / 33 / 33 0.29
Turku / Oulu / Tampere 51 / 91 / 49 64 / 69 /58 74 / 62 / 55 77 / 52 / 62 0.003
Season (January-March)/ (April-June) /
(July-September) / (October-
December)
74 / 53 / 10 / 54 65 / 54 / 22 / 50 54 / 46 / 43 / 48 17 / 29 / 112 / 33 <0.001
Girls / boys 82 / 109 70 / 121 81 / 110 77 / 114 0.58
Old HLA high/moderate 50 / 141 68 / 123 64 / 127 64 / 127 0.20
New HLA (NA/nonincreased
slight/moderate/high)
34 / 9 / 40 / 70 / 37 27 / 8 / 33 / 80 / 43 51 / 11 / 29 / 52 / 48 26 / 7 / 33 / 77 / 48 0.027
Median ponderal index,
kg/m3 (IQR)
27.84
(26.31–29.60)
27.71
(26.37–29.44)
27.59
(25.88–29.11)
27.55
(25.71–29.10)
0.12
Median weight, kg (IQR) 3.61 (3.28–3.95) 3.68 (3.36–3.97) 3.63 (3.28–3.93) 3.53 (3.27–3.90) 0.28
Median height, cm (IQR) 51 (49–52) 51 (49–52) 51 (49–52) 50 (49–52) 0.77
Mothers nonsmoking/smoking/NA 160 / 21 / 10 163 / 15 / 10 170 / 17 / 4 162 / 14 / 15 0.70
Cases with IAA/GAD
appearing first
31 / 26 28 / 31 34 / 19 30 / 33 0.25
Children with 0/1/2/3/4
autoantibodies
81 / 2 / 20 / 28 / 55 105 / 1 / 23 / 22 / 38 106 / 2 / 16 / 26 / 40 88 / 1 / 19 / 33 / 44 0.37
The value of P , 0.05 (two-tailed) was taken to indicate statistical significance and is marked in bold.
aMedian 25(OH)D (range), nmol/L.
doi: 10.1210/jc.2018-02094 https://academic.oup.com/jcem 2281
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/104/6/2277/5289723 by Tam
pere U
niversity Library D
ept of H
ealth Sciences user on 28 M
ay 2019
nine in summer, and eight in fall. Because the nutritional
information was based on the eighth month of pregnancy,
the season was mostly the same as the season of birth.
Discussion
Based on this study, fetal vitamin D status, reflected by
umbilical cord serum 25(OH)D (15–17), does not appear
to have an association with IA or with progression to
T1D. The 25(OH)D concentrations of the pregnant
mothers are lower than in the children in the upcoming
months and years (2). The levels in cord serum or plasma
seemed to be low worldwide (18, 19) until recently (17).
Vitamin D supplementation is recommended for the
whole growth period for all children in Finland and the
parents comply well with this recommendation, at least for
the first few years of life (20). The conspicuous monthly
variation and the overall low 25(OH)D concentrations
alone suggest that the pregnant women have not been
taking commonly vitamin D supplementation, and this
was confirmed by the nutritional data available. Similarly,
in an earlier study of 1669 mothers from the same pop-
ulation cohort in Tampere and Oulu, the mean maternal
intake of vitaminDwas 5.1 (SD 2.6)mg from food and 1.4
(SD 2.6) mg from supplements, with only 32% of women
taking vitamin D supplements during approximately the
same study period, i.e., years 1997 to 2001 (21). It is
noteworthy thatwe found no seasonal variation in vitamin
D supplement usage, even though the recommendations
advised pregnant women to use supplements only during
Table 3. General Characteristics of the Subpopulation Participating in Nutritional Study During Pregnancy
Group T1D+ n = 121 T1D2 n = 119 IA+ n = 63 IA2 n = 60 P
Oulu/Tampere 51 / 70 49 / 70 35 / 28 33 / 27 0.11
Mother of a boy/girl 54 / 67 52 / 67 26 / 37 24 / 36 0.94
Age of mother, y (median
[IQR])
29.6
(26.5–34.2)
29.3
(26.7–33.2)
28.4
(25.2–32.7)
29.1
(26.8–33.0)
0.76
Birth weight, kg (median [IQR]) 3.5 (3.2–3.9) 3.7
(3.3–4.0)
3.6
(3.2–3.9)
3.6
(3.3–4.0)
0.56
Birth height, m (median [IQR]) 0.50
(0.49–0.52)
0.51
(0.49–0.52)
0.51
(0.49–0.52)
0.50
(0.49–0.52)
0.81
Ponderal index, kg/m3
(median [IQR])
27.9
(26.4–29.5)
28.3
(26.3–29.5)
27.7
(26.1–28.7)
27.7
(26.4–29.6)
0.34
Energy intake per day, kJ
(median [IQR])
10,876
(8842–13,062)
10,876
(9808–13,094)
11,364
(9666–12,976)
11,354
(9364–12,656)
0.38
Vitamin D intake per day from food,
mg (median [IQR])
4.92
(3.47–6.69)
5.24
(3.75–7.74)
5.22
(3.45–7.01)
4.71
(2.94–6.51)
0.21
Vitamin D intake per day from
supplements, mg (median [IQR])
0
(0–2.11)
0
(0–1.5)
0
(0–2.39)
0
(0–0.76)
0.85
Total vitamin D intake per day, mg
(median [IQR])
5.84
(3.91–8.96)
6.53
(4.06–9.84)
5.96
(4.09–9.29)
6.53
(4.06–9.84)
0.38
The value of P , 0.05 (two-tailed) was taken to indicate statistical significance.
Table 4. Nutritional Data During the Eighth Month of Pregnancy When Divided Into the Same 25(OH)D
Concentration Quarters as the Entire Data Set in Table 2
Q1 Q2 Q3 Q4
20.14
(9.40–24.00)a
27.75
(24.00–31.06)a
34.95
(31.06–41.72)a
49.27
(41.76–135.1)a P
Median 25(OH)D (range)
of subcohort, nmol/L
20.53
(9.40–24.00)
27.76
(24.00–31.06)
35.12
(31.11–41.72)
50.06
(41.76-105.1)
N of children with nutritional
data during pregnancy
103 87 88 85 0.23
Vitamin D intake from food per day,
mg (median [IQR])
4.25
(2.95–5.86)
4.83
(3.54–6.84)
4.94
(3.58–6.95)
6.43
(4.29–9.25)
0.007
Vitamin D intake from supplements
per day, mg (median [IQR])
0 (0–0) 0
(0–1.50)
0
(0–3.99)
0
(0–2.97)
<0.001
Total vitamin D intake per day,
mg (median [IQR])
4.76
(3.15–6.10)
5.91
(3.72–8.62)
7.26
(4.16–9.17)
8.43
(5.09–12.00)
<0.001
Energy intake per day, kJ (median
[IQR])
11,107
(9424–12,976)
11,051
(8922–13,789)
11,220
(8905–13,298)
11,617 (
10,000–13,490)
0.71
The value of P , 0.05 (two-tailed) was taken to indicate statistical significance and is marked in bold.
aOriginal median 25(OH)D (range), nmol/L.
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the winter months (22–24). Thus, it seems that most
Finnish mothers did not take care of their own vitamin D
supplementation during pregnancy at the time but were
careful in supplementation of their children.
The major strength of the current study is that it
includes a large number of children in matched case
control pairs and there is abundant follow-up data on
these children. Collecting samples for more than a
decade is not an easy task to accomplish but it helps
minimize annual fluctuations.
Some study limitations should also be considered. One
is that the children were originally selected for the DIPP
study based on their HLA-DQB1 genotype and we did not
have any genetic information on the mothers. No asso-
ciation of HLA-DRB1 or HLA-DQB1 with 25(OH)D
concentrations has been reported to the best of our
knowledge, but an association of cord serum 25(OH)D
concentrations andmaternalHLA-B44 (25) and two single
nucleotide polymorphisms, one for the vitamin D receptor
gene and one for the group-specific component gene (26),
have been observed in Finnish studies. Furthermore, we
did not have single nucleotide polymorphisms of the vi-
tamin D pathway in the children, which might have been
interesting to have, as some of us, participating in a large
international collaboration study, found that 25(OH)D
levels and vitamin D receptor polymorphism may have a
combined role in the development of islet autoimmunity in
children at increased genetic risk for T1D (27).
It is noteworthy that the case children in this study
were born evenly around the year in both case groups,
those who developed T1D and those remaining auto-
antibody positive. This alone should indicate that the
25(OH)D concentration at birth may not be as important
in the development of T1D as previously suggested (14).
In an updated analysis of the same individuals of that
previous Norwegian study, no association between first
and second trimester 25(OH)D concentrations and
childhood risk of T1D was observed (28). By analyzing
neonatal blood spots, a small Italian study found no
association between 25(OH)D levels and risk of T1D,
except in a subgroup of migrant infants (29). A Danish
research group showed with a larger cohort that that
neonatal 25(OH)D status was not associated with a later
risk of T1D (30). We were able to verify those results and
went further, as we showed for the first time that 25(OH)D
levels at birth were not associated with the progression to
clinical T1D, the number of islet autoantibodies, nor with
which autoantibodies appear first.
This and the other studies in which no differences
regarding later risk of T1D was observed (10, 11), had
very low median 25(OH)D levels. It might be possible
that a difference could be detected in a more vitamin D
sufficient population. However, in another autoimmune
disease, multiple sclerosis, it was the lower spectrum of
levels where the risk of the disease was most prominent
(12). Accordingly it is unlikely that there is any detectable
difference in relation to T1D, which was further sup-
ported by our finding that no difference were seen even in
the highest 25(OH)D concentration quartile where the
median levels were very close to normal.
Cord serum 25(OH)D concentrations may have a long-
term influence on later health and associations have been
reported with childhood metabolic profiles (31) and early
childhood growth together with neural development (32).
Maternal vitamin D levels have been shown to have more
influence on cord serum 25(OH)D than the genetic factors
of the offspring (16). As we showed here, maternal intake
of vitamin D during pregnancy has a clear impact on cord
serum 25(OH)D levels and quite surprisingly, vitamin D
intake was not associated with energy intake or maternal
age. The factors behind the higher 25(OH)D concentra-
tions in the cord serum samples of older mothers, which
has been reported also in other studies (33, 34), would
require further research.
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